Back to Browse Journals » Drug Design, Development and Therapy » Volume 4

Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective

Authors Richard Kones

Published Date December 2010 Volume 2010:4 Pages 383—413

DOI http://dx.doi.org/10.2147/DDDT.S10812

Published 9 December 2010

Richard Kones
The Cardiometabolic Research Institute, Houston, TX, USA

Abstract: The major public health concern worldwide is coronary heart disease, with dyslipidemia as a major risk factor. Statin drugs are recommended by several guidelines for both primary and secondary prevention. Rosuvastatin has been widely accepted because of its efficacy, potency, and superior safety profile. Inflammation is involved in all phases of atherosclerosis, with the process beginning in early youth and advancing relentlessly for decades throughout life. C-reactive protein (CRP) is a well-studied, nonspecific marker of inflammation which may reflect general health risk. Considerable evidence suggests CRP is an independent predictor of future cardiovascular events, but direct involvement in atherosclerosis remains controversial. Rosuvastatin is a synthetic, hydrophilic statin with unique stereochemistry. A large proportion of patients achieve evidence-based lipid targets while using the drug, and it slows progression and induces regression of atherosclerotic coronary lesions. Rosuvastatin lowers CRP levels significantly. The Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial was designed after the observation that when both low density lipoprotein and CRP were reduced, patients fared better than when only LDL was lowered. Advocates and critics alike acknowledge that the benefits of rosuvastatin in JUPITER were real. After a review, the US Food and Drug Administration extended the indications for rosuvastatin to include asymptomatic JUPITER-eligible individuals with one additional risk factor. The American Heart Association and Centers of Disease Control and Prevention had previously recognized the use of CRP in persons with "intermediate risk" as defined by global risk scores. The Canadian Cardiovascular Society guidelines went further and recommended use of statins in persons with low LDL and high CRP levels at intermediate risk. The JUPITER study focused attention on ostensibly healthy individuals with "normal" lipid profiles and high CRP values who benefited from statin therapy. The backdrop to JUPITER during this period was an increasing awareness of a rising cardiovascular risk burden and imperfect methods of risk evaluation, so that a significant number of individuals were being denied beneficial therapies. Other concerns have been a high level of residual risk in those who are treated, poor patient adherence, a need to follow guidelines more closely, a dual global epidemic of obesity and diabetes, and a progressively deteriorating level of physical activity in the population. Calls for new and more effective means of reducing risk for coronary heart disease are intensifying. In view of compelling evidence supporting earlier and aggressive therapy in people with high risk burdens, JUPITER simply offers another choice for stratification and earlier risk reduction in primary prevention patients. When indicated, and in individuals unwilling or unable to change their diet and lifestyles sufficiently, the benefits of statins greatly exceed the risks. Two side effects of interest are myotoxicity and an increase in the incidence of diabetes.

Keywords: rosuvastatin, JUPITER study, statin drugs, C-reactive protein, dyslipidemia, cholesterol, primary prevention, cardiovascular risk, coronary heart disease, inflammation, low-density lipoprotein, high-density lipoprotein, diabetes, metabolic syndrome, Framingham risk score, Reynolds risk score, coronary artery calcification, carotid intima-media thickness, hypertension, obesity, HMG CoA reductase, mevalonate, prenylation, statin myopathy, pleiotropic, dolichol

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Efficacy and safety of rosuvastatin in the management of dyslipidemia

Paolo Rubba, Gennaro Marotta, Marco Gentile

Vascular Health and Risk Management 2009, 5:343-352

Published Date: 7 April 2009

Emerging strategies and therapies for treatment of Paget’s disease of bone

Michou L, Brown JP

Drug Design, Development and Therapy 2011, 5:225-239

Published Date: 26 April 2011

Current perspectives on rosuvastatin

Hu M, Tomlinson B

Integrated Blood Pressure Control 2013, 6:15-25

Published Date: 18 April 2013

Hematological profile of normal pregnant women in Lagos, Nigeria

Akinbami AA, Ajibola SO, Rabiu KA, Adewunmi AA, Dosunmu AO, Adediran A, Osunkalu VO, Osikomaiya BI, Ismail KA

International Journal of Women's Health 2013, 5:227-232

Published Date: 3 May 2013

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema

Messenger WB, Beardsley RM, Flaxel CJ

Drug Design, Development and Therapy 2013, 7:425-434

Published Date: 24 May 2013